Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Indivior Pharmaceuticals (INDV) Inventory (2021 - 2025)

Indivior Pharmaceuticals (INDV) has 4 years of Inventory data on record, last reported at $153.0 million in Q4 2025.

  • For Q4 2025, Inventory fell 8.38% year-over-year to $153.0 million; the TTM value through Dec 2025 reached $153.0 million, down 8.38%, while the annual FY2025 figure was $153.0 million, 8.38% down from the prior year.
  • Inventory reached $153.0 million in Q4 2025 per INDV's latest filing, down from $167.0 million in the prior quarter.
  • Across five years, Inventory topped out at $167.0 million in Q4 2024 and bottomed at $114.0 million in Q4 2022.
  • Average Inventory over 4 years is $140.0 million, with a median of $139.5 million recorded in 2023.
  • Peak YoY movement for Inventory: surged 32.54% in 2024, then fell 8.38% in 2025.
  • A 4-year view of Inventory shows it stood at $114.0 million in 2022, then rose by 10.53% to $126.0 million in 2023, then soared by 32.54% to $167.0 million in 2024, then dropped by 8.38% to $153.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Inventory were $153.0 million in Q4 2025, $167.0 million in Q4 2024, and $126.0 million in Q4 2023.